CY1112871T1 - Μεθοδος κι ενδιαμεσες ενωσεις - Google Patents
Μεθοδος κι ενδιαμεσες ενωσειςInfo
- Publication number
- CY1112871T1 CY1112871T1 CY20121100548T CY121100548T CY1112871T1 CY 1112871 T1 CY1112871 T1 CY 1112871T1 CY 20121100548 T CY20121100548 T CY 20121100548T CY 121100548 T CY121100548 T CY 121100548T CY 1112871 T1 CY1112871 T1 CY 1112871T1
- Authority
- CY
- Cyprus
- Prior art keywords
- unions
- preparation
- derivatives
- intermediates
- matanthinoid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
- C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds
Abstract
Μέθοδοι παρασκευής παραγώγων Ν-μεθυλο-L-αλανίνης και νέες ενδιάμεσες ενώσεις της μεθόδου. Τα παράγωγα και οι ενδιάμεσες ενώσεις είναι χρήσιμα για την παρασκευή συμπλεγμάτων μέσου κυτταρικής σύνδεσης/μαιτανσινοειδών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23178400P | 2000-09-12 | 2000-09-12 | |
EP01975197A EP1322597B1 (en) | 2000-09-12 | 2001-09-12 | Process and intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112871T1 true CY1112871T1 (el) | 2016-04-13 |
Family
ID=22870636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100548T CY1112871T1 (el) | 2000-09-12 | 2012-06-15 | Μεθοδος κι ενδιαμεσες ενωσεις |
Country Status (11)
Country | Link |
---|---|
US (2) | US6570024B2 (el) |
EP (1) | EP1322597B1 (el) |
JP (1) | JP4886961B2 (el) |
AR (1) | AR030612A1 (el) |
AT (1) | ATE555078T1 (el) |
AU (1) | AU2001294549A1 (el) |
CY (1) | CY1112871T1 (el) |
DK (1) | DK1322597T3 (el) |
ES (1) | ES2383792T3 (el) |
PT (1) | PT1322597E (el) |
WO (1) | WO2002022554A1 (el) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
WO2002092771A2 (en) | 2001-05-11 | 2002-11-21 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
EA013323B1 (ru) * | 2004-12-09 | 2010-04-30 | Сентокор, Инк. | Иммуноконъюгаты против интегрина, способы и варианты применения |
MX2009007987A (es) | 2007-01-25 | 2010-03-01 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
US9023356B2 (en) | 2007-03-15 | 2015-05-05 | Ludwig Institute For Cancer Research Ltd | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途 |
PL2437785T3 (pl) | 2009-06-04 | 2015-08-31 | Novartis Ag | Sposoby identyfikacji miejsc sprzęgania IgG |
JP2012531212A (ja) | 2009-07-03 | 2012-12-10 | アビペップ ピーティーワイ リミテッド | イムノコンジュゲート及びその作製方法 |
CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
SG181814A1 (en) | 2009-12-23 | 2012-07-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
CN114246952A (zh) | 2010-06-08 | 2022-03-29 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
RS64791B1 (sr) | 2011-05-27 | 2023-11-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - vezujući proteini |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2014182970A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
AU2014348552A1 (en) | 2013-11-13 | 2016-06-02 | Zymeworks Inc. | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof |
KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
US11420981B2 (en) * | 2019-04-18 | 2022-08-23 | Indena S.P.A. | Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof |
WO2022248870A1 (en) | 2021-05-28 | 2022-12-01 | Glaxosmithkline Intellectual Property Development Limited | Combination therapies for treating cancer |
CA3233953A1 (en) | 2021-10-05 | 2023-04-13 | Matthew Bruce | Combination therapies for treating cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE430062B (sv) * | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
JPS61112042A (ja) * | 1985-07-31 | 1986-05-30 | Wakunaga Seiyaku Kk | 架橋試薬として適当な化合物 |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
JP3408158B2 (ja) * | 1998-07-17 | 2003-05-19 | 大日本製薬株式会社 | スルトプリド誘導体及び抗スルトプリド抗体 |
US6573074B2 (en) * | 2000-04-12 | 2003-06-03 | Smithkline Beecham Plc | Methods for ansamitocin production |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
-
2001
- 2001-09-05 AR ARP010104219A patent/AR030612A1/es unknown
- 2001-09-12 JP JP2002526755A patent/JP4886961B2/ja not_active Expired - Fee Related
- 2001-09-12 PT PT01975197T patent/PT1322597E/pt unknown
- 2001-09-12 AU AU2001294549A patent/AU2001294549A1/en not_active Abandoned
- 2001-09-12 WO PCT/US2001/028443 patent/WO2002022554A1/en active Application Filing
- 2001-09-12 US US10/009,381 patent/US6570024B2/en not_active Expired - Lifetime
- 2001-09-12 AT AT01975197T patent/ATE555078T1/de active
- 2001-09-12 ES ES01975197T patent/ES2383792T3/es not_active Expired - Lifetime
- 2001-09-12 DK DK01975197.3T patent/DK1322597T3/da active
- 2001-09-12 EP EP01975197A patent/EP1322597B1/en not_active Expired - Lifetime
-
2003
- 2003-03-17 US US10/390,252 patent/US6884874B2/en not_active Expired - Lifetime
-
2012
- 2012-06-15 CY CY20121100548T patent/CY1112871T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2383792T3 (es) | 2012-06-26 |
WO2002022554A1 (en) | 2002-03-21 |
AR030612A1 (es) | 2003-08-27 |
US20020156318A1 (en) | 2002-10-24 |
EP1322597A4 (en) | 2005-10-19 |
PT1322597E (pt) | 2012-06-01 |
US20040014980A1 (en) | 2004-01-22 |
JP2004509094A (ja) | 2004-03-25 |
JP4886961B2 (ja) | 2012-02-29 |
EP1322597B1 (en) | 2012-04-25 |
AU2001294549A1 (en) | 2002-03-26 |
EP1322597A1 (en) | 2003-07-02 |
DK1322597T3 (da) | 2012-07-02 |
US6884874B2 (en) | 2005-04-26 |
ATE555078T1 (de) | 2012-05-15 |
US6570024B2 (en) | 2003-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112871T1 (el) | Μεθοδος κι ενδιαμεσες ενωσεις | |
CY1105963T1 (el) | Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης | |
CY1109160T1 (el) | Πυρiδinοamiνες ως ρυθμιστες αγγειογενεσης | |
ATE264863T1 (de) | 28-epirapaloge | |
CY1110000T1 (el) | Ενωσεις οκταϋδροβενζιμιδαζολονης ως αναλγητικα | |
CY1106133T1 (el) | Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης | |
NO20054715L (no) | Fremgangsmater og mellomprodukter for fremstilling av anti-cancer forbindelser | |
EP1583603A4 (en) | WATER-SOLUBLE PRODUCTS AND METHODS OF MAKING AND USING THE SAME | |
ES2184149T3 (es) | Paclitaxeles 6-tio sustituidos. | |
DK1412317T3 (da) | Retinoidderivater med antiangiogenetisk-, antitumor og pro-apoptotisk virkning | |
ATE256138T1 (de) | 9-oximsilyl erythromycin a derivate | |
DE60122216D1 (de) | Zolpidem Hemitartrat Solvat | |
NO20051393L (no) | Prosess og intermediater for fremstilling av tienopyrrol-derivater | |
CY1108300T1 (el) | Παρασκευασματα ευγενων μεταλλων και παρασκευασματα λουστρων για την αμεση και εμμεση μεταξοτυπια | |
IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
IS2174B (is) | Setnar fenýl-píperasín afleiður, framleiðsla þeirra og notkun | |
NO20021124L (no) | Fremgangsmåte for fremstilling av benzoksazinderivater og mellomprodukter derfor | |
CY1106376T1 (el) | Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν | |
IL154776A0 (en) | Method for the preparation of 21-hydroxy-6, 19-oxidoprogesterone and derivatives thereof | |
WO2003084926A3 (en) | Polymeric acyl derivatives of indoles | |
IS4980A (is) | Aðferðir og milliefni við framleiðslu á setnum krómanól afleiðum | |
PT1307436E (pt) | Processo para a preparacao de derivados de bacatina iii | |
NO20020308D0 (no) | Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten | |
CY1106306T1 (el) | Παραγωγα 5-ιμινο-13-δεοξυ ανθρακυκλινης, οι χρησεις τους και διepγασιες παρασκευης αυτων | |
ATE476980T1 (de) | Acylderivate des 4-demethylpenclomedins, verwendung und zubereitung derselben |